As part of a previously reported trial comparing granulocyte-colony stimulating factor (G-CSF) stimulated bone marrow and peripheral blood stem cells (PBSCs) in allogeneic stem cell transplantation, we included a questionnaire to compare donor morbidity and long-term complications between the two donation procedures. Bone marrow donation was associated with significantly more donors experiencing localized pain at the donation site compared to PBSC collection. However, this was not associated with any increased delay in returning to normal activity. Although a minority of bone marrow donors suffered chronic pain at the donation site, no serious long-term side effects relating to G-CSF stimulated stem cell donation were identified.
cell; source Allogeneic bone marrow transplantation is an established therapy for many haematologic disorders. Although stem cells for use in bone marrow transplantation have traditionally been harvested directly from the iliac crests under general anaesthesia, with use of granulocyte-colony stimulating factor (G-CSF), mobilization of peripheral blood stem cells (PBSCs) is becoming increasingly common. More recently, harvest of G-CSF stimulated bone marrow has also been reported. [1] [2] [3] Although potential complications and psychological consequences of stem cell donation in allogeneic bone marrow transplantation are well documented, [4] [5] [6] [7] [8] [9] [10] [11] [12] very few comparisons between the source of stem cells and donor outcomes have been reported. 13, 14 Similarly, very little data are available on potential long-term consequences of administration of G-CSF to normal donors. [15] [16] [17] [18] As part of a previously published prospective randomized trial comparing G-CSF stimulated bone marrow and PBSCs for use in allogeneic stem cell transplantation, 3 we included a questionnaire to compare donor morbidity and long-term complications between the two donation procedures.
Materials and methods
A total of 57 consecutive human leucocyte antigen (HLA)-matched sibling donors involved in a prospective randomized study comparing G-CSF stimulated bone marrow to PBSCs for use in allogeneic stem cell transplantation were included. 3 A further two donors excluded from the original trial because of HLA-antigen mismatches were also included in the current analysis. Randomization to bone marrow or PBSC collection was performed in permuted blocks of four donors, stratified according to risk of disease recurrence in the recipient, as previously described. 3 G-CSF was administered at a dose of 10 mg/kg/day SC as a single evening injection to all donors for 5 days prior to stem cell collection. Donors randomized to bone marrow stem cell donation underwent bilateral posterior superior iliac crest aspiration under general anaesthesia. At completion of the bone marrow harvest, 10 ml of 0.5% bupivacaine was infiltrated to the periostium at the harvest site as previously described. 19 Regular paracetamol and/or paracetamol and codeine were used for postharvest analgesia. All bone marrow donors received 1 U of autologous blood post harvest. Donors were discharged from hospital on the same day of donation when possible.
Donors randomized to PBSC collections underwent a standard leukapheresis on a continuous flow blood cell separator (COBE Laboratories, Lakewood, USA). Venous access was obtained via peripheral venipuncture of both arms. The procedure was performed on one or two consecutive days on an outpatient basis.
A questionnaire to assess donor morbidity was posted to all donors at 28 days, 3 months, 12 months and 24 months post stem cell collection. The questionnaire was qualitative in design and asked donors to comment on the presence or absence of fatigue, pain at donation site, lower back pain, difficulty with walking, sleeping difficulties, light-headedness, fainting, bleeding and any other symptoms that donors felt may be related to the donation procedure. Donors were also asked to estimate the time taken to return to normal activity post stem cell donation, and to list diagnoses of any new medical problems.
The two-tailed Fisher's exact test was used to analyse differences in response rates and symptoms experienced between the two donor groups.
Results
A total of 30 bone marrow and 29 PBSC donors were included. There was no significant difference in sex or age of donors between the two groups, nor between the number of responses received from each group at any of the time points studied (Table 1) .
Post (Table 2) .
A minority of donors of both groups reported persistent lower back pain at 24 months ( Table 2 ). Three of the four bone marrow donors who suffered lower back pain at this time also reported persistent pain at the donation site. The other three donors suffering lower back pain at 24 months (one bone marrow donor and two PBSC donors) felt that the pain was unrelated to the donation procedure.
Time taken to return to normal activity was no different between the two groups. For bone marrow donors, median time to return to normal activity was 7 days (range o7-120 days). For PBSC donors, median time to return to normal activity was also 7 days (range o7-90 days). In total, 14 of 22 and 15 of 26 responders reported to have returned to normal activity within 7 days of bone marrow vs PBSC collection respectively (P ¼ 0.77).
To date, two donor deaths have occurred, both within the PBSC donor group. One donor died from an acute myocardial infarct at 23 months and a second from a subarachnoid haemorrhage (because of a ruptured berry aneurysm) at 28 months post stem cell donation respectively. Aside from a probable vocal cord adenoma in one PBSC donor 7 months after donation, no other malignancy or significant medical condition had developed in any responder on follow-up at 24 months.
Discussion
A previous randomized study of donor experiences between nonstimulated bone marrow donation and G-CSF stimulated PBSC collection reported similar levels of physical discomfort complicating both collection procedures, though more rapid resolution of symptoms in the PBSC donor group.
14 Our study compares donor outcomes between G-CSF stimulated bone marrow and PBSC donation. Although our data are purely qualitative, we have shown that donation of G-CSF stimulated bone marrow is associated with significantly more donors experiencing localized pain at the donation site compared to PBSC collection. Despite the greater number of bone marrow donors experiencing pain related to the donation procedure, however, this was not associated with any increased delay in returning to normal activity.
A significant minority of bone marrow donors (18%) who responded to the 24-month questionnaire reported persisting pain at the donation site. The chronic nature of post harvest pain experienced by these individuals is not well described in the literature. [4] [5] [6] 12, 14 Our data suggest that medical follow-up should be offered to donors post stem cell donation to allow any chronic pain issues to be identified and managed appropriately.
A previous report has suggested that high-dose G-CSF administered to normal donors may result in a transient prothrombotic state. 20 We do not feel that the cardiac Bone marrow donors  28 days  25  17  20  19  12  7  6  0  2  3 months  20  7  8  8  4  3  3  0  1  12 months  20  2  2  4  1  2  3  0  0  24 months  17  2  3  4  0  1  0  0  0   Peripheral blood donors 28 days  27  15  5  16  8  11  11  3  1  3 months  21  6  0  4  2  2  1  0  0  12 months  22  8  0  1  0  1  2  0  0  24 months  18  2  0  2  0  2  1  0  0 death suffered by our donor almost 2 years post donation was related to the G-CSF administered during the donation procedure. Similar to previous reports, 15 no unusual medical conditions were noted to have occurred on follow-up at 24 months.
There are several limitations to our study. Firstly, the sample sizes are relatively small. Secondly, our data are purely qualitative in nature. Lastly, information was only collected relating to donor morbidity after completion of stem cell donation. Data regarding differences in donor morbidity during the actual donation procedures themselves were not obtained.
In conclusion, we have shown that although donation of G-CSF-stimulated bone marrow is associated with significantly more donors experiencing localized pain at the donation site compared to PBSC collection, it is not associated with any increased delay in returning to normal activity. Although a minority of bone marrow donors suffered chronic pain at the donation site, no serious longterm side effects relating to G-CSF-stimulated stem cell donation were identified.
